Genmab Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Genmab
Actionable Strategy Starts Here
Genmab’s BCG Matrix snapshot highlights how its monoclonal antibody portfolio maps against market growth and relative share—identifying potential Stars in late-stage oncology, Cash Cows from established collaborations, and Question Marks tied to emerging indications. This concise view surfaces strategic trade-offs around R&D spend, licensing, and lifecycle management while flagging lower-return assets that may warrant divestment. The full BCG Matrix report delivers quadrant-by-quadrant data, actionable recommendations, and editable Word + Excel files to guide investment and product decisions—purchase now for instant access.
Stars
Epcoritamab (EPKINLY/TEPKINLY)
Epcoritamab (EPKINLY/TEPKINLY) is Genmab’s star: a bispecific CD3xCD20 antibody driving growth in large B-cell lymphoma and expanding into follicular lymphoma, with global 2025 revenue of about $2.1 billion and estimated 45% share in later-line US/Europe settings as of Q3 2025.
Tisotumab Vedotin (TIVDAK)
Tisotumab Vedotin (TIVDAK) is a first-in-class antibody-drug conjugate for cervical cancer, occupying a dominant spot in a high-growth oncology niche with global sales reaching about $620m in 2024 and projected CAGR ~18% through 2028.
Full FDA and EMA approvals in 2023–2024 and label expansion into second-line and earlier lines boosted uptake, making TIVDAK one of Genmab’s top revenue drivers with estimated 2025 revenue share ~28%.
Genmab continues heavy clinical investment—>30 ongoing trials as of Jan 2026—targeting combinations and earlier lines to defend against rising ADC competitors and sustain market leadership.
HexaBody-CD38 (GEN3014)
HexaBody-CD38 (GEN3014) is a next-generation anti-CD38 engineered antibody aimed to outperform daratumumab with enhanced potency and cytotoxicity; Genmab reports Phase 1/2 responses with overall response rates up to 70% in relapsed MM cohorts as of 2025.
The drug sits in a high-growth segment as the market shifts to subcutaneous formats and combo regimens; global CD38 market projected at ~$6.2B in 2024 with 7–9% CAGR to 2030, favoring GEN3014 adoption.
Scaling requires heavy capex and clinical spend—Genmab disclosed R&D + manufacturing investments of ~€400–€550M annually in 2024—yet GEN3014 anchors the company’s hematology franchise potential.
DuoBody-PD-L1x4-1BB (GEN1046)
DuoBody-PD-L1x4-1BB (GEN1046), co-developed with BioNTech, is a bispecific targeting PD-L1 and 4-1BB for solid tumors, addressing a global oncology market valued at ~$200B in 2024 and growing ~8% annually; GEN1046 shows strong uptake in refractory trial cohorts with reported objective response rates up to ~25% in early-phase studies.
Genmab/BioNTech have funded >$600M across multi-indication trials through 2025, signaling intent to position GEN1046 as a backbone therapy; its wide indication breadth and trial momentum place it as a potential Star in Genmab’s BCG matrix.
- Targets solid tumors; market ~$200B (2024)
- ORR ~25% in refractory cohorts (early data)
- R&D spend >$600M to 2025 for multi-indication trials
- High uptake in clinical populations → strong market share potential
Amivantamab (RYBREVANT)
Amivantamab (RYBREVANT) is a Star in Genmab’s BCG matrix: Janssen leads global commercialization while Genmab earns royalties and co-development upside thanks to its DuoBody bispecific platform.
It gained rapid share in NSCLC with exon 20 insertion EGFR mutations after FDA accelerated approval in 2021; 2024 sales reported by Janssen ~USD 380m YTD, and EGFR-mutant lung cancer segment CAGR ~18% keeps it high-growth for 2025.
- Genmab role: DuoBody tech, royalties + co-dev
- Commercial lead: Janssen
- Indication: NSCLC, EGFR exon20 insertions
- 2024 sales: ~USD 380m (Janssen reported YTD)
- Market growth: EGFR-mutant lung cancer CAGR ~18%
Genmab's 2025 Stars: Epcoritamab €2.0B, TIVDAK €0.55B, GEN3014 ORR 70%
Epcoritamab, Tisotumab Vedotin, GEN3014 and GEN1046 are Stars for Genmab: 2025 revenue ≈€2.0B (epcoritamab), €0.55B (TIVDAK), GEN3014 shows ORR up to 70% in relapsed MM, GEN1046 ORR ~25%; R&D spend €400–550M (2024), partnership funding >€600M to 2025.
| Asset | 2025 rev | ORR | Notes |
|---|---|---|---|
| Epcoritamab | €2.0B | — | 45% later-line share |
| TIVDAK | €0.55B | — | CAGR ~18% to 2028 |
| GEN3014 | — | 70% | CD38 market €6.2B (2024) |
| GEN1046 | — | 25% | Funding >€600M |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Genmab: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest recommendations and trend context
Customizable Excel Spreadsheet
One-page Genmab BCG Matrix placing each business unit in a quadrant for rapid strategic decisions
Cash Cows
Daratumumab (DARZALEX)
DARZALEX (daratumumab) remains the gold standard for multiple myeloma and in 2025 continues to drive Genmab’s royalty income—Genmab reported EUR 2.1bn royalties in 2024, largely from DARZALEX. The CD38 antibody market is mature; DARZALEX holds a dominant, stable share (~45–55% global CD38 unit share in 2024). It generates large excess cash flow that funds Genmab’s R&D pipeline; maintenance capex is minimal versus royalties, enabling >EUR 1.5bn annual reinvestment capacity.
Ofatumumab (KESIMPTA)
Ofatumumab (KESIMPTA) treats relapsing multiple sclerosis and sits in a mature market; global MS drug sales were about $26.5bn in 2024 and growth slowed to ~3% annually.
Under the Novartis partnership, Genmab earned royalty revenue estimated at ~$220m in 2024, high-margin income requiring no Genmab marketing spend.
It functions as a cash cow: low sales growth but steady, high-margin royalties that fund R&D and pipeline investment.
Tepezza (Teprotumumab)
Tepezza (teprotumumab), approved for thyroid eye disease, uses Genmab’s antibody technology and generated roughly $85m in royalties and milestones for Genmab in 2024, giving a steady cash stream.
The orbital disease market is established with limited direct competitors for this indication, so Genmab passively harvests returns while the partner manages supply, marketing, and clinical operations.
DuoBody Technology Platform
DuoBody Technology Platform is Genmab’s cash cow: industry-standard bispecific antibody tech with 30+ partnerships (e.g., Janssen, Biogen) and >€1.2bn in disclosed upfront and milestone payments through 2024, yielding high-margin licensing revenue with minimal incremental R&D costs.
It funds Genmab’s pipeline and ecosystem expansion, providing predictable cash flow while enabling co-development deals that boost long-term value.
- 30+ partner deals as of 2024
- €1.2bn disclosed payments through 2024
- High gross margins due to low incremental cost
- Supports pipeline funding and ecosystem growth
Rybrevant Royalty Stream
Rybrevant royalties sit in the cash cows quadrant: indications are mature with high market penetration and stabilized growth—global revenues for Rybrevant partners reached about $420m in 2024, yielding Genmab mid-teens percentage royalties and roughly $60–70m cash inflow in 2024.
These predictable royalties fund Genmab’s shift to a fully integrated biotech, covering late-stage development and manufacturing investments; partner-led commercialization keeps Genmab’s operating spend lower and cash conversion high.
- 2024 partner sales ≈ $420m
- Genmab 2024 royalty cash ≈ $60–70m
- High penetration, stabilized growth
- Partner-led commercialization → higher cash conversion
High‑margin royalties from DARZALEX, DuoBody, KESIMPTA & more fund Genmab R&D
DARZALEX, KESIMPTA, Tepezza, DuoBody and Rybrevant generate steady, high‑margin royalties (Genmab 2024 royalties EUR 2.1bn; DuoBody >€1.2bn disclosed payments; Rybrevant partner sales ~$420m → Genmab ~$60–70m; Tepezza ~$85m; Novartis KESIMPTA ~ $220m), funding R&D and late‑stage development.
| Asset | 2024 cash | role |
|---|---|---|
| DARZALEX | EUR 2.1bn (royalties) | Primary cash cow |
| DuoBody | >€1.2bn (payments) | Licensing cash cow |
Full Transparency, Always
Genmab BCG Matrix
The file you're previewing is the exact Genmab BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. It reflects the same market-backed positioning, growth-share categorizations, and strategic recommendations included in the downloadable version. After purchase, the complete document is sent directly to your inbox and is immediately editable, printable, and presentation-ready for meetings or client use. No surprises—just a professional BCG Matrix built for strategic clarity.
Dogs
Early-Stage Monoclonal Legacy Assets
Several older, monospecific antibody candidates at Genmab have been deprioritized as the industry pivots to bispecifics and ADCs; these programs sit in low-growth segments—global monoclonal antibody market growth ~3% CAGR (2021–25) vs bispecifics/ADCs >20% CAGR.
They face crowded competition and Genmab lacks a clear advantage; pipeline review shows these assets absorb minimal admin spend (~<5% of R&D overhead) but project negligible NPV and limited strategic value.
Discontinued Rare Disease Programs
Certain niche non-oncology programs at Genmab, notably discontinued rare-disease candidates, show minimal uptake and missed 2024–2025 clinical milestones, leaving estimated annualized sales potential under $20m and market shares below 1% in stagnant segments.
Genmab lacks scale in these small markets—R&D and SG&A burn per program exceeded $15–25m in 2024—so divestiture or termination would cut ongoing cash traps and free capital for core oncology assets.
Generic Competitor Exposed Small Molecules
Legacy collaborations on older small-molecule and biologic formats have lost share to low-cost biosimilars and generics, shrinking volumes by ~40% in key EU markets since 2019 and cutting gross margins below 10% by 2024.
In low-growth segments (CAGR <1%), these lines became unprofitable to support; Genmab has largely exited such partnerships, reallocating ~€150–200m annual R&D spend toward proprietary antibody programs.
Non-Core Research Tools
Legacy research reagents and diagnostic tools from Genmab’s early years no longer fit its 2025 oncology focus and show negligible sales versus therapeutics; revenues likely under €5m annually compared with Genmab’s ~€2.5bn 2024+ therapeutic revenue run-rate.
These products sit in slow-moving markets with low growth and <1% share of company R&D spend, offering minimal strategic value versus high-margin, high-growth monoclonal antibody pipeline.
- Minimal revenue: ≈€<5m
- Company revenue share: <1%
- Pipeline value: >€2.5bn run-rate 2024
- Recommendation: divest or spin-off
Underperforming Regional Partnerships
Specific regional collaborations for Genmab’s older antibody franchises—notably partnerships in Southeast Asia and parts of Eastern Europe—have failed to gain share against entrenched local incumbents, yielding market share under 5% and revenue growth near 0–2% annually in 2024.
These ventures typically only break even after marketing and regulatory costs; several generated sub-$5m annual net revenue in 2024, so Genmab is prioritizing exits to redeploy resources to global alliances with double-digit CAGR.
- Low share: <5% in targeted regions (2024)
- Growth: 0–2% CAGR (recent year)
- Revenue: many ties ≤$5m in 2024
- Strategy: exit noncore deals, focus on high-growth global partners
Divest legacy non-oncology assets to free €150–200m for €2.5bn oncology run-rate
Genmab’s legacy low-growth antibody and non-oncology assets show <€5m revenue each, <1% company share, 0–2% growth; R&D/SG&A burn €15–25m per program (2024). Recommendation: divest/spin-off to free €150–200m R&D for core oncology; pipeline therapeutic run-rate ≈€2.5bn (2024).
| Metric | Value (2024) |
|---|---|
| Revenue per legacy asset | ≈€<5m |
| Company revenue share | <1% |
| Growth | 0–2% CAGR |
| R&D/SG&A burn | €15–25m/program |
| Redeployable R&D | €150–200m |
| Therapeutic run-rate | ≈€2.5bn |
Question Marks
GEN1042 (DuoBody-CD40x4-1BB)
GEN1042 (DuoBody-CD40x4-1BB) sits in Genmab’s Question Marks quadrant: clinical growth is rapid—Phase 1/2 trials in solid tumors expanded in 2024 with ~120 patients enrolled—yet market share is near zero and competition includes PD-1/PD-L1 drugs with $30B+ combined 2024 sales.
Advancing to a Star needs heavy R&D: Genmab’s oncology spend rose to DKK 3.1bn in 2024; expect hundreds of millions more over 2–4 years to prove superiority versus checkpoint inhibitors. If trials fail or marginally beat standard care, the asset risks becoming a Dog as the checkpoint market consolidates and biosimilars grow.
GEN1053 (HexaBody-CD27)
GEN1053 (HexaBody-CD27) is an early-stage immunotherapy targeting the CD27 co-stimulatory pathway, a field showing 18% CAGR in oncology investment 2021–25 and increasing trial activity across 40+ CD27/CD137 programs as of 2025.
It holds zero market share, not yet commercialized, so revenue is nil and future uptake is uncertain given competitors advancing to Phase 2/3.
Genmab must choose: accelerate spend (estimated development cost ~USD 300–400M to approval) to gain first-mover advantage or partner/license to share risk and conserve cash.
GEN1056 (DuoBody-CD3x5T4)
GEN1056 (DuoBody-CD3x5T4) sits in the Question Marks quadrant: a bispecific T‑cell engager targeting solid tumors in a crowded market that was worth $6.8B in 2024 and projected to reach $18.2B by 2030 (CAGR ~17.5%).
Promising mechanism, but market-share capture vs established bispecifics and checkpoint combos is uncertain; Genmab’s 2024 R&D spend was DKK 4.6B, highlighting funding intensity.
Late‑stage trials typically cost $200–400M; advancing GEN1056 will demand high cash burn and likely partnership or capital raises to de‑risk commercial rollout.
Expansion into Autoimmune Indications
Genmab is piloting its antibody platforms into autoimmune indications—markets growing ~6–9% annually and worth ~US$150–200bn by 2025—yet its programs hold low market share due to early clinical stages and limited validation.
Commercial success hinges on clear differentiation versus established biologics (e.g., Humira, Enbrel) and on readouts from current phase 1/2 studies expected 2025–2026.
- Market size ~US$150–200bn (2025)
- Autoimmune CAGR ~6–9% (2020–25)
- Genmab programs: early clinical, low share
- Key risk: differentiation vs Humira/Enbrel
Next-Gen Antibody-Drug Conjugates (ADCs)
Next-Gen ADCs for novel tumor antigens are high-growth opportunities with low current share for Genmab; global ADC market forecast was $9.6B in 2025 rising to ~$18B by 2030 (Allied Market Research), so success could be transformative.
These programs are cash-intensive—R&D and CMC costs often exceed $200–400M per ADC—and face technical hurdles in linker stability, payload toxicity, and target validation, making timelines 5–8 years to approval.
They fit a wait-and-see BCG quadrant: heavy investment now to de-risk clinical proof; if Phase II readouts fail, write-offs are likely, but a single approval can drive >$500M annual peak sales.
- High growth, low share
- R&D/CMC costs ~$200–400M per program
- 5–8 year development timeline
- Binary outcome: high upside (> $500M peak) or write-off
Genmab at a Crossroads: Invest $300–400M/program to Scale or Partner to De‑risk
Genmab’s Question Marks: multiple early/mid‑stage oncology and autoimmune programs (GEN1042, GEN1053, GEN1056, ADCs) show rapid clinical growth but near‑zero market share; 2024 R&D was DKK 4.6bn–3.1bn per program area, typical late‑stage costs $200–400M, ADC peak sales potential >$500M; choice: invest ~USD300–400M/program to scale or partner to share risk.
| Asset | Stage | 2024 R&D (DKK) | Dev cost est (USD) | Peak sales est |
|---|---|---|---|---|
| GEN1042 | Phase1/2 | 3.1bn | 300–400M | 200–800M |
| GEN1053 | Early | — | 300–400M | 100–500M |
| GEN1056 | Mid | 4.6bn | 200–400M | 300–700M |
| ADCs | Pre/early | — | 200–400M | >500M |